A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

University of Michigan Rogel Cancer Center

Status and phase: Terminated; Phase 2

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Treatments: Drug: Docetaxel; Drug: AT-101

Study type: Interventional

Funder types: Other

Identifiers

NCT01285635

UMCC 2010.031

HUM00040432 (Other Identifier)

Details and patient eligibility

About

This study will examine the effects of an investigational drug called AT-101 in combination with an FDA approved cancer drug called Docetaxel. It is hoped that AT-101 will help the Docetaxel to have a better effect in slowing or stopping cancer cell growth. This study will help the researchers learn what effects, if any, the combination of AT-101 and Docetaxel has on your cancer. For instance, will the combination cause your tumor(s) to shrink or stop growing? The researchers will also learn about the safety of the combination of AT-101 and Docetaxel. For instance, are there any side effects? If so, what kind of side effects does the combination cause? How severe are the side effects, and how often do they occur?

Enrollment: 35 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Males and non-pregnant, non-lactating females at least 18 years old.

2. Histologically or cytologically confirmed diagnosis of SCCHN (Squamous Cell Carcinoma of the Head and Neck).

3. Stage IVC (metastatic), or advanced, locally recurrent SCCHN not amenable to surgery or palliative radiotherapy.

4. Presence of measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors)

   a. If the only site of measurable disease for this study is within a prior field of irradiation, then the sum of the longest diameter (SLD) of that lesion must have increased by at least 20% from the prior treatment nadir

5. Received no more than two prior systemic chemotherapeutic regimen for SCHNN in the locally advanced or metastatic setting and have relapsed after or be refractory to therapy

   • Systemic therapies given in the adjuvant setting or with chemoradiotherapy are counted only if the patient relapses after 6 months of the last cycle of chemotherapy or the completion of radiation
   • Included as systemic chemotherapy regimens (but not limited to) are patients who may have received erlotinib (Tarceva®) or another EGFR inhibitor. Previous treatment with paclitaxel (but not docetaxel) is permitted.

6. ECOG performance status ≤ 1 (Appendix 2)

7. Expected survival of at least 3 months

8. Adequate liver and renal and bone marrow function as indicated by:

   • Serum creatinine ≤ 2.0 times the upper limit of normal, AND
   • Serum albumin ≥ 3.0 gm/dL, AND
   • Total bilirubin ≤ 1.0 times the upper limit of normal, AND
   • Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN) for the testing laboratory. Note: For patients with alkaline phosphatase ≥ 2.5 x ULN, the AST and ALT must be ≤ 1.5 x ULN
   • Hemoglobin ≥ 9 g/dL (may be post-transfusion);
   • Platelet count ≥ 100 x103 cells/mm3
   • Neutrophil count ≥1500 cells/mm3

9. Negative pregnancy test for females of childbearing potential

10. Willingness to use contraception by a method that is deemed effective by the Investigator by both males and female patients of childbearing potential (postmenopausal women must have been amenorrheal for at least 12 months to be considered of non-childbearing potential) and their partners throughout the treatment period and for at least 30 days following the last dose of AT-101

11. Ability to understand and the willingness to sign a written informed consent form; the consent form must be signed by the patient prior to any study-specific procedures

12. Willingness and ability to comply with study procedures and follow-up examination

Exclusion criteria

1. Pregnant or nursing women.
2. Prior docetaxel treatment for SCCHN in the metastatic setting.
3. Treatment of SCCHN with chemotherapy within 28 days of the first dose of study treatment. Acute toxicities from prior therapy must have resolved to Grade ≤ 1. Patients whose disease responded to the most recently administered prior regimen must have documented progression of disease subsequent to that regimen, to be eligible.
4. Treatment with monoclonal antibody (e.g., VEGF or EGFR targeting antibody) within 45 days prior to the first dose of study treatment. Acute toxicities from prior therapy must have resolved to Grade ≤ 1. Patients whose disease responded to the most recently administered prior regimen must have documented progression of disease subsequent to that regimen, to be eligible.
5. Treatment of SCCHN with radiotherapy within 14 days of the first dose of study treatment. Prior radiotherapy is permissible only if the lesions used for determination of disease activity (i.e., target lesions) were not previously irradiated, or have increased in size since the completion of radiotherapy, and the patient has fully recovered from any toxicity of the radiotherapy.
6. Treatment of SCCHN with erlotinib within 14 days of the first dose of study treatment. Acute toxicities from prior therapy must have resolved to Grade ≤ 1. Patients whose disease responded to the most recently administered prior regimen must have documented progression of disease subsequent to that regimen, to be eligible.
7. Any concurrent therapy intended to treat SCCHN.
8. Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
9. Symptomatic hypercalcemia or hypercalcemia that is > Grade 2.
10. Participation in any investigational drug study within 28 days prior to study treatment. (Patient must have recovered from all acute effects of previously administered investigational agents).
11. Active secondary malignancy or history of other malignancy within the last five years (patients who have been disease-free for five years, or have a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible).
12. Active symptomatic fungal, bacterial and/or viral infection including active HIV. Note: protocol does not require screening for viruses; however, patients with known active infections are excluded.
13. Patients who are contraindicated for treatment with docetaxel.
14. Have malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel disease, partial or complete small bowel obstruction.
15. Uncontrolled CNS (Central Nervous System) metastases. Patients with known, previously treated CNS metastases are eligible if they are neurologically stable, as per the investigating physician's clinical assessment, and do not require steroids at the time of study entry.
16. Prior use of gossypol or AT-101, or known hypersensitivity to gossypol or AT-101.
17. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
18. Any patient being treated for acute deep vein thrombosis or patients with a history of recurrent deep vein thrombosis independent of treatment with anticoagulation.
19. Any other condition or circumstance that would, in the opinion of the Investigator, make the patient unsuitable for participation in the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

35 participants in 3 patient groups

Docetaxel Alone

Active Comparator group

Treatment:

Drug: Docetaxel

Pulse Dose AT-101 Arm

Experimental group

Treatment:

Drug: AT-101

Drug: Docetaxel

Metronomic AT-101 Arm

Experimental group

Treatment:

Drug: AT-101

Drug: Docetaxel